Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients (APIs) and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #2 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 31 Mar 2026 | A. Lakshmi | Immediate relative | Sell | 0 | ₹0 |
| 29 Dec 2025 | Donepudi Sita | Immediate relative | Buy | 0 | ₹0 |
| 29 Dec 2025 | P. Rama Sekhar | Employee / designated person | Sell | 0 | ₹0 |
| 11 Dec 2025 | L. Lakshmi | Immediate relative | Buy | 0 | ₹0 |
| 11 Dec 2025 | SUDHEER KUMAR LINGAMNENI | Employee / designated person | Sell | 0 | ₹0 |
| 11 Sep 2025 | S Krishna Sree | Immediate relative | Sell | 0 | ₹0 |
| 11 Sep 2025 | S. RAMA KRISHNA | Employee / designated person | Sell | 0 | ₹0 |
| 2 Jul 2025 | K. Sridevi | Immediate relative | Sell | 0 | ₹0 |
| 13 Jun 2025 | K. Sridevi | Immediate relative | Sell | 0 | ₹0 |
| 11 Jun 2025 | Yalavarthi Vamsi Krishna | Immediate relative | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 9 Oct 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 33,108 | 6120.5000 | NSE |
| 9 Oct 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 33,108 | 6120.5000 | NSE |
| 14 Jul 2025 | THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849 | Block | Buy | 21,874 | 6835.0000 | NSE |
| 14 Jul 2025 | THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828 | Block | Sell | 21,874 | 6835.0000 | NSE |
| 6 Nov 2024 | PRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITED | Block | Sell | 80,324 | 5979.6500 | NSE |
| 6 Nov 2024 | PI OPPORTUNITIES AIF V LLP | Block | Buy | 80,324 | 5979.6500 | NSE |
| 20 Oct 2023 | NORTHERN LIGHTS FUND TRUST III RONDURE NEW WORLD FUND | Block | Buy | 43,478 | 3637.7000 | BSE |
| 20 Oct 2023 | RONDURE NEW WORLD FUND | Block | Sell | 43,478 | 3637.7000 | BSE |
| 3 Nov 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 209,125 | 3781.4500 | NSE |
| 3 Nov 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 209,125 | 3781.4500 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 24 Jul 2026 | Dividend - Rs 30 Per Share | 30.0000 | 24 Jul 2026 |
| 25 Jul 2025 | Dividend - Rs 30 Per Share | 30.0000 | 25 Jul 2025 |
| 2 Aug 2024 | Dividend - Rs 30 Per Share | 30.0000 | 2 Aug 2024 |
| 11 Aug 2023 | Dividend - Rs 30 Per Share | 30.0000 | 11 Aug 2023 |
| 11 Aug 2022 | Dividend - Rs 30 Per Share | 30.0000 | 12 Aug 2022 |
| 17 Aug 2021 | Dividend - Rs 20 Per Share | 20.0000 | — |
| 25 Feb 2020 | Interim Dividend - Rs 16 Per Share | 16.0000 | 26 Feb 2020 |
| 14 Aug 2019 | Annual General Meeting/Dividend - Rs 16 Per Share | 16.0000 | — |
| 31 Aug 2018 | Annual General Meeting/Dividend- Rs 10 Per Share | 10.0000 | — |
| 15 Sep 2017 | Annual General Meeting/Dividend - Rs 10/- Per Share | 10.0000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 23 Sep 2015 | BONUS | Bonus 1:1 |
| 30 Jul 2009 | BONUS | Bonus-1:1 |
| 3 Aug 2007 | SPLIT | Agm/Fv Split Rs10 To Rs2 |
| 4 Sep 2020 | OTHER | Annual General Meeting |
| 18 Aug 2016 | OTHER | Annnual General Meeting |
| 15 Jun 2009 | AGM | Agm/Div-Rs.6/- Per Share |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 1 Aug 2026 | Financial Results | Yes |
| 23 May 2026 | Financial Results/Dividend | Yes |
| 11 Feb 2026 | Financial Results | Yes |
| 7 Nov 2025 | Financial Results | Yes |
| 6 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 100, NIFTY 100, NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY NEXT 50, NIFTY NEXT 50, NIFTY PHARMA, NIFTY PHARMA, NIFTY100 ALPHA 30
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
